The changing therapeutic landscape of head and neck cancer

By J. Cramer, B. Burtness, Quynh-Thu Le, R. Ferris. Nature Reviews Clinical Oncology, 2019

637 citations recorded by the source corpus.

Subfields: Otorhinolaryngology, Surgery

View Paper: https://www.semanticscholar.org/paper/7f4e6b968ff5ef1894f02ca7a1ea713a0afb8e82

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Kalyan Saginala
2. Prashanth Rawla
3. Alexander Barsouk
4. Adam Barsouk
5. J. Aluru

Citations in the corpus

• Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma (2023, background): “The increase in survival among developed nations has been multifactorial, including the shift to HPV-related cases (which portend better prognosis), earlier detection due to screening, advances in robotic surgical resection and stereotactic radiation, as well as the development of immunotherapies (c”
• TROP2 expression in head and neck squamous cell carcinoma: association with the tumor immune microenvironment and clinical outcome (2026, unknown): “Immune checkpoint inhibition targeting the PD-1/PD-L1 axis has reshaped the therapeutic landscape in recurrent or metastatic HNSCC (4).”